The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare

by MMS Holdings and MichBio.org

This webinar is intended to help guide individuals towards a better understanding of core concepts and requirements for using real-world data (RWD). Here, we will delve into how one can derive and utilize real-world evidence (RWE) in drug development, from the perspective of a clinical trial programmer/data analyst. We will discuss the potential opportunities that can generate RWD to improve the safety, efficiency, and quality in a clinical paradigm. The knowledge shared in this presentation echoes the regulatory guidance’s for use of RWE. Evolving standards that are necessary to make the most out of RWD, demonstration projects, and first-hand experience with some technical tools will be discussed. Combining it all together should provide the tools and knowledge to navigate more confidently through this less explored, but complex landscape of RWD and RWE.

Speakers include:

  • Narasimha Ayyalas, Manager, Statistical Programming, MMS Holdings
  • Aditya Gadiko, Senior Clinical Programmer, MMS Holdings
  • Susheel Arkala, Manager, Statistical Programming, MMS Holdings
  • Chris Hurley, Associate Director, Data Sciences, MMS Holdings
  • Ravi Yandamuri, Principal Clinical Programmer, MMS Holdings

Suggested For You

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer

perspectives

August 13th, 2024

How To Navigate The Nonclinical Evaluation Landscape Of Biopharmaceuticals

perspectives

August 5th, 2024

Ensuring Robust Data Privacy and Protection: An Overview of the MMS Framework

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma